Meisner Lara

CIK 00018839862 companiesBOSTON, MA

SEC Profile

Transactions

Companies

Filings

CIK

0001883986

Recent Transactions

50 trades

Exercise/Conversion
Bicara Therapeutics Inc.$BCAX
Common Stock
2025-09-29$9.24/sh+33,807→ 33,807 total
Exercise/Conversion
Bicara Therapeutics Inc.$BCAX
Stock Option (Right to Buy)
2025-09-29−33,807→ 101,423 total
Sale
Bicara Therapeutics Inc.$BCAX
Common Stock
2025-09-29$14.75/sh−33,807→ 0 total
Sale
Bicara Therapeutics Inc.$BCAX
Common Stock
2025-09-15$11.49/sh−15,829→ 0 total
Exercise/Conversion
Bicara Therapeutics Inc.$BCAX
Stock Option (Right to Buy)
2025-09-15−9,744→ 87,699 total
Exercise/Conversion
Bicara Therapeutics Inc.$BCAX
Stock Option (Right to Buy)
2025-09-15−6,085→ 54,769 total
Exercise/Conversion
Bicara Therapeutics Inc.$BCAX
Common Stock
2025-09-15$5.45/sh+15,829→ 15,829 total
Exercise/Conversion
Bicara Therapeutics Inc.$BCAX
Stock Option (Right to Buy)
2025-06-16−6,085→ 60,854 total
Exercise/Conversion
Bicara Therapeutics Inc.$BCAX
Common Stock
2025-06-16$5.45/sh+15,829→ 15,829 total
Sale
Bicara Therapeutics Inc.$BCAX
Common Stock
2025-06-16$10.43/sh−15,829→ 0 total
Exercise/Conversion
Bicara Therapeutics Inc.$BCAX
Stock Option (Right to Buy)
2025-06-16−9,744→ 97,443 total
Exercise/Conversion
Bicara Therapeutics Inc.$BCAX
Stock Option (Right to Buy)
2025-03-14−30,246→ 67,119 total
Exercise/Conversion
Bicara Therapeutics Inc.$BCAX
Stock Option (Right to Buy)
2025-03-14−48,720→ 107,187 total
Sale
Bicara Therapeutics Inc.$BCAX
Common Stock
2025-03-14$13.24/sh−30,620→ 0 total
Exercise/Conversion
Bicara Therapeutics Inc.$BCAX
Common Stock
2025-03-14$5.45/sh+79,146→ 79,145 total
Sale
Bicara Therapeutics Inc.$BCAX
Common Stock
2025-03-14$12.69/sh−48,526→ 30,620 total
Sale
Viridian Therapeutics, Inc.\DE$VRDN
Common Stock
2023-06-16$28.35/sh−27→ 29,971 total
Exercise/Conversion
Viridian Therapeutics, Inc.\DE$VRDN
Common Stock
2023-06-16$23.03/sh+27→ 29,998 total
Exercise/Conversion
Viridian Therapeutics, Inc.\DE$VRDN
Stock Option (Right to Buy)
2023-06-16−28→ 37,453 total
Exercise/Conversion
Viridian Therapeutics, Inc.\DE$VRDN
Stock Option (Right to Buy)
2023-06-15−2,269→ 37,481 total
Exercise/Conversion
Viridian Therapeutics, Inc.\DE$VRDN
Common Stock
2023-06-15$23.03/sh+2,269→ 32,240 total
Sale
Viridian Therapeutics, Inc.\DE$VRDN
Common Stock
2023-06-15$28.02/sh−2,269→ 29,971 total
Sale
Viridian Therapeutics, Inc.\DE$VRDN
Common Stock
2023-06-06$25.02/sh−5,126→ 29,971 total
Exercise/Conversion
Viridian Therapeutics, Inc.\DE$VRDN
Common Stock
2023-06-06$18.51/sh+5,126→ 35,097 total
Exercise/Conversion
Viridian Therapeutics, Inc.\DE$VRDN
Stock Option (Right to Buy)
2023-06-06−5,126→ 84,375 total
Exercise/Conversion
Viridian Therapeutics, Inc.\DE$VRDN
Common Stock
2023-06-05$18.51/sh+499→ 30,470 total
Exercise/Conversion
Viridian Therapeutics, Inc.\DE$VRDN
Stock Option (Right to Buy)
2023-06-05−499→ 89,501 total
Sale
Viridian Therapeutics, Inc.\DE$VRDN
Common Stock
2023-06-05$25.03/sh−499→ 29,971 total
Exercise/Conversion
Viridian Therapeutics, Inc.\DE$VRDN
Stock Option (Right to Buy)
2023-06-02−1,875→ 18,128 total
Sale
Viridian Therapeutics, Inc.\DE$VRDN
Common Stock
2023-06-02$24.21/sh−1,875→ 29,971 total
Exercise/Conversion
Viridian Therapeutics, Inc.\DE$VRDN
Common Stock
2023-06-02$14.00/sh+1,875→ 31,846 total
Sale
Viridian Therapeutics, Inc.\DE$VRDN
Common Stock
2023-03-09$29.07/sh−29,971→ 0 total
Award
Viridian Therapeutics, Inc.\DE$VRDN
Stock Option (Right to Buy)
2023-02-08+108,000→ 108,000 total
Exercise/Conversion
Viridian Therapeutics, Inc.\DE$VRDN
Common Stock
2023-01-23$23.03/sh+4,971→ 4,971 total
Exercise/Conversion
Viridian Therapeutics, Inc.\DE$VRDN
Stock Option (Right to Buy)
2023-01-23−1,872→ 20,003 total
Sale
Viridian Therapeutics, Inc.\DE$VRDN
Common Stock
2023-01-23$35.66/sh−6,843→ 0 total
Exercise/Conversion
Viridian Therapeutics, Inc.\DE$VRDN
Stock Option (Right to Buy)
2023-01-23−4,971→ 39,750 total
Exercise/Conversion
Viridian Therapeutics, Inc.\DE$VRDN
Common Stock
2023-01-23$14.00/sh+1,872→ 6,843 total
Sale
Viridian Therapeutics, Inc.\DE$VRDN
Common Stock
2022-12-21$29.19/sh−16,326→ 0 total
Exercise/Conversion
Viridian Therapeutics, Inc.\DE$VRDN
Common Stock
2022-12-21$23.03/sh+16,326→ 16,326 total
Exercise/Conversion
Viridian Therapeutics, Inc.\DE$VRDN
Stock Option (Right to Buy)
2022-12-21−16,326→ 44,721 total
Exercise/Conversion
Viridian Therapeutics, Inc.\DE$VRDN
Stock Option (Right to Buy)
2022-12-20−600→ 61,047 total
Sale
Viridian Therapeutics, Inc.\DE$VRDN
Common Stock
2022-12-20$28.07/sh−600→ 0 total
Exercise/Conversion
Viridian Therapeutics, Inc.\DE$VRDN
Common Stock
2022-12-20$23.03/sh+600→ 600 total
Exercise/Conversion
Viridian Therapeutics, Inc.\DE$VRDN
Common Stock
2022-12-16$23.03/sh+1,297→ 1,297 total
Sale
Viridian Therapeutics, Inc.\DE$VRDN
Common Stock
2022-12-16$28.44/sh−1,297→ 0 total
Exercise/Conversion
Viridian Therapeutics, Inc.\DE$VRDN
Stock Option (Right to Buy)
2022-12-16−1,297→ 61,647 total
Exercise/Conversion
Viridian Therapeutics, Inc.\DE$VRDN
Stock Option (Right to Buy)
2022-12-15−300→ 62,944 total
Sale
Viridian Therapeutics, Inc.\DE$VRDN
Common Stock
2022-12-15$28.08/sh−300→ 0 total
Exercise/Conversion
Viridian Therapeutics, Inc.\DE$VRDN
Common Stock
2022-12-15$23.03/sh+300→ 300 total

Companies

Recent Filings

Address

116 HUNTINGTON AVENUE, SUITE 703

BOSTON, MA, 02116

View on SEC.gov